Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708679 | 1.00 | CASR (0.47) | CASRNPC1TSHRGRM2RORC | |
| SCHEMBL7711555 | 0.88 | TSHR (0.39) | CASRNPC1TSHRGRM2RORC | |
| SCHEMBL7708641 | 0.83 | ALDH1A1 (0.43) | POLBGAA | |
| SCHEMBL7711502 | 0.79 | ITGB3 (0.41) | KCNH2 | |
| SCHEMBL7705256 | 0.75 | GRM2 (0.39) | NPC1TSHRGRM2OPRM1KCNH2 | |
| SCHEMBL7708663 | 0.74 | POLB (0.46) | CASRTSHRPOLBGAA | |
| SCHEMBL7711755 | 0.74 | GAA (0.39) | NPC1TSHRRORCGAA | |
| Hydrochloric Acid SCHEMBL6854351 | 0.73 | GRM2 (0.39) | CASRGRM2RORCSIGMAR1 | |
| SCHEMBL7705262 | 0.72 | TSHR (0.47) | TSHR | |
| SCHEMBL6860836 | 0.70 | FFAR4 (0.42) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | ITGB1, ITGA1, ITGB3 | CASR 602/4885NPC1 2263/4885TSHR 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.